Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Organisation › Details

MolMed S.p.A. (MLMD.MI)

MolMed S.p.A. is a medical biotechnology company focused on research, development, clinical validation and manufacturing of novel cell and gene therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immunosuppression prophylaxis, currently in Phase III in high risk leukaemias and recommended by CHMP for Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours exerting antitumor activity through its specific binding to blood vessels that feed the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immunogene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from discovery to market, including scale-up and cGMP production of market-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI). *

 

Products Industry gene therapy
  Industry 2 biopharmaceutical
     
  Street 58 via Olgettina
  City 20132 Milan
  Tel +39-02-21277-1
    Address record changed: 2013-05-16
     
Basic data Employees n. a.
     
    * Document for �About Section�: MolMed S.p.A.. (6/24/16). "Press Release: MolMed Receives Positive CHMP Opinion Recommending Conditional Marketing Authorisation for Zalmoxis". Milan.
     
   
Record changed: 2017-11-26

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for MolMed S.p.A. (MLMD.MI)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top